Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Validity evidence supports the use of automated neuropsychological assessment metrics as a screening tool for cognitive impairment in lupus.

Tayer-Shifman OE, Green R, Beaton D, Ruttan L, Wither JE, Tartaglia MC, Kakvan M, Lombardi S, Anderson N, Su J, Bonilla D, Zandy M, Choi MY, Fritzler MJ, Touma Z.

Arthritis Care Res (Hoboken). 2019 Oct 18. doi: 10.1002/acr.24096. [Epub ahead of print]

PMID:
31628718
2.

Associations among classification criteria items within systemic lupus erythematosus.

Touma Z, Cervera R, Brinks R, Lorenzoni V, Tani C, Hoyer BF, Costenbader KH, Sebastiani GD, Navarra SV, Bonfa E, Ramsey-Goldman R, Tedeschi SK, Dörner T, Johnson SR, Aringer M, Mosca M; ACR/EULAR group, New SLE classification criteria for clinical research are being developed, sponsored by EULAR, ACR.

Arthritis Care Res (Hoboken). 2019 Sep 27. doi: 10.1002/acr.24078. [Epub ahead of print]

PMID:
31560454
3.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
4.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

5.

Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis.

Moustafa AT, Moazzami M, Engel L, Bangert E, Hassanein M, Marzouk S, Kravtsenyuk M, Fung W, Eder L, Su J, Wither JE, Touma Z.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(18)30563-8. doi: 10.1016/j.semarthrit.2019.06.017. [Epub ahead of print] Review.

PMID:
31303437
6.

Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE.

Webber D, Cao J, Dominguez D, Gladman DD, Levy DM, Ng L, Paterson AD, Touma Z, Urowitz MB, Wither JE, Silverman ED, Hiraki LT.

Rheumatology (Oxford). 2019 Jun 24. pii: kez220. doi: 10.1093/rheumatology/kez220. [Epub ahead of print]

PMID:
31236574
7.

Drs. Tayer-Shifman and Touma reply.

Tayer-Shifman OE, Touma Z.

J Rheumatol. 2019 Jun;46(6):653. doi: 10.3899/jrheum.181290. No abstract available.

PMID:
31154447
8.

Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus.

Kwan A, Marzouk S, Ghanean H, Kishwar A, Anderson N, Bonilla D, Vitti M, Su J, Touma Z.

Semin Arthritis Rheum. 2019 Oct;49(2):260-266. doi: 10.1016/j.semarthrit.2019.03.004. Epub 2019 Mar 9.

PMID:
30940467
9.

Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ).

Otobo TM, Conaghan PG, Maksymowych WP, van der Heijde D, Weiss P, Sudol-Szopinska I, Herregods N, Jaremko JL, Meyers AB, Rumsey D, Inarejos EC, Kirkhus E, Stimec J, Panwar J, Thorpe K, Jans L, van Rossum MA, Tolend M, Perez M, Tzaribachev N, Sandhya P, Tse S, Simone A, Swami VG, Touma Z, Lambert R, Doria AS.

J Rheumatol. 2019 Sep;46(9):1192-1197. doi: 10.3899/jrheum.181115. Epub 2019 Feb 15.

PMID:
30770500
10.

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.

Bangert E, Wakani L, Merchant M, Strand V, Touma Z.

Patient Relat Outcome Meas. 2019 Jan 9;10:1-7. doi: 10.2147/PROM.S134326. eCollection 2019. Review.

11.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2019 Jan;28(1):114-122. doi: 10.1177/0961203318817132. Epub 2018 Dec 8.

PMID:
30526328
12.

The Assessment of Anxiety and Depression and its Associated Factors in SLE.

Kwan A, Katz P, Touma Z.

Curr Rheumatol Rev. 2019;15(2):90-98. doi: 10.2174/1573397114666180926101513. Review.

PMID:
30255761
13.

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.

Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.

PMID:
30249507
14.

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.

Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N.

J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

15.

Novel biological therapeutic approaches to cutaneous lupus erythematosus.

Tayer-Shifman OE, Rosen CF, Wakani L, Touma Z.

Expert Opin Biol Ther. 2018 Oct;18(10):1041-1047. doi: 10.1080/14712598.2018.1513484. Epub 2018 Sep 5. Review.

PMID:
30118337
16.

Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus.

Keeling SO, Vandermeer B, Medina J, Chatterley T, Nevskaya T, Pope J, Alaburubalnabi Z, Bissonauth A, Touma Z.

J Rheumatol. 2018 Oct;45(10):1448-1461. doi: 10.3899/jrheum.171310. Epub 2018 Aug 15.

17.

Subcutaneous belimumab in the treatment of systemic lupus erythematosus.

Elalouf O, Keeling SO, Touma Z.

Immunotherapy. 2018 Sep;10(13):1163-1173. doi: 10.2217/imt-2018-0061. Epub 2018 Aug 14. Review.

PMID:
30105936
18.

Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):822-828. doi: 10.1002/acr.23720. Epub 2019 May 10.

PMID:
30055090
19.

Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, Touma Z.

Arthritis Rheumatol. 2019 Jan;71(1):91-98. doi: 10.1002/art.40674. Epub 2018 Nov 26.

PMID:
30035365
20.

Psoriatic Arthritis Sonographic Enthesitis Instruments: A Systematic Review of the Literature.

Elalouf O, Bakirci Ureyen S, Touma Z, Anderson M, Kaeley GS, Aydin SZ, Eder L.

J Rheumatol. 2019 Jan;46(1):43-56. doi: 10.3899/jrheum.171466. Epub 2018 Jul 15.

PMID:
30008458
21.

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome.

Alharbi S, Ahmad Z, Bookman AA, Touma Z, Sanchez-Guerrero J, Mitsakakis N, Johnson SR.

J Rheumatol. 2018 Oct;45(10):1406-1410. doi: 10.3899/jrheum.170953. Epub 2018 Jul 15.

PMID:
30008448
22.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
23.

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans.

Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, Chaudhary K, Munn DH, Tsirigos A, Madaio M, Gabrielsson S, Touma Z, Wither J, De Carvalho DD, McGaha TL.

Nat Immunol. 2018 Jun;19(6):571-582. doi: 10.1038/s41590-018-0107-1. Epub 2018 May 14.

24.

Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms.

Wither JE, Prokopec SD, Noamani B, Chang NH, Bonilla D, Touma Z, Avila-Casado C, Reich HN, Scholey J, Fortin PR, Boutros PC, Landolt-Marticorena C.

PLoS One. 2018 May 9;13(5):e0196117. doi: 10.1371/journal.pone.0196117. eCollection 2018.

25.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
26.

Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.

McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):545-551. Epub 2018 Apr 13.

27.

Minimal Clinically Important Difference: A Review of Outcome Measure Score Interpretation.

Engel L, Beaton DE, Touma Z.

Rheum Dis Clin North Am. 2018 May;44(2):177-188. doi: 10.1016/j.rdc.2018.01.011. Epub 2018 Feb 21. Review.

PMID:
29622290
28.

What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis.

Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, Mustafa A, Su J, Lambiris P, Mosca M, Touma Z.

Semin Arthritis Rheum. 2018 Oct;48(2):240-255. doi: 10.1016/j.semarthrit.2018.02.007. Epub 2018 Feb 21.

PMID:
29571540
29.

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Touma Z, Gladman DD.

Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. eCollection 2017. Review.

30.

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort.

Fung WA, Su J, Touma Z.

Biomed Res Int. 2017;2017:5312960. doi: 10.1155/2017/5312960. Epub 2017 Aug 21.

31.

Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis.

Medina-Rosas J, Fung WA, Su J, Touma Z.

Semin Arthritis Rheum. 2018 Feb;47(4):557-564. doi: 10.1016/j.semarthrit.2017.07.012. Epub 2017 Aug 3.

PMID:
28888363
32.

Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus.

Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z.

J Rheumatol. 2017 Nov;44(11):1583-1589. doi: 10.3899/jrheum.161125. Epub 2017 Sep 1.

PMID:
28864643
33.

Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus.

Medina-Rosas J, Su J, Cook RJ, Sabapathy A, Touma Z.

J Clin Rheumatol. 2017 Sep;23(6):301-307. doi: 10.1097/RHU.0000000000000557.

PMID:
28816766
35.

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.

Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.

Rheumatol Int. 2017 Jun;37(6):865-873. doi: 10.1007/s00296-017-3682-9. Epub 2017 Mar 9.

36.

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease.

Al Rayes H, Harvey PJ, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2017 Feb 10;19(1):31. doi: 10.1186/s13075-017-1240-1.

37.

The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.

Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z.

Semin Arthritis Rheum. 2017 Jun;46(6):791-797. doi: 10.1016/j.semarthrit.2016.09.008. Epub 2016 Sep 21.

PMID:
27769590
38.

Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus.

Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z.

Lupus. 2017 Apr;26(4):365-372. doi: 10.1177/0961203316664597. Epub 2016 Aug 20.

PMID:
27522094
39.

Reply.

Polachek A, Touma Z, Anderson M, Eder L.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):457. doi: 10.1002/acr.23001. No abstract available. Erratum in: Arthritis Care Res (Hoboken). 2019 Apr;71(4):574.

40.

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

Medina-Rosas J, Al-Rayes H, Moustafa AT, Touma Z.

Expert Opin Biol Ther. 2016 Oct;16(10):1225-38. doi: 10.1080/14712598.2016.1214263. Epub 2016 Jul 29. Review.

PMID:
27429254
41.

Systemic lupus erythematosus.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G.

Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39. Review.

PMID:
27306639
42.

Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.

Polachek A, Touma Z, Anderson M, Eder L.

Arthritis Care Res (Hoboken). 2017 Jan;69(1):67-74. doi: 10.1002/acr.22926. Erratum in: Arthritis Care Res (Hoboken). 2019 Apr;71(4):574.

43.

Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study.

Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook RJ, Gladman DD.

J Rheumatol. 2016 Jun;43(6):1057-62. doi: 10.3899/jrheum.150466. Epub 2016 Apr 1.

PMID:
27036389
44.

Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus.

Fidler L, Keen KJ, Touma Z, Mittoo S.

Lupus. 2016 Aug;25(9):1004-11. doi: 10.1177/0961203316630818. Epub 2016 Feb 3.

PMID:
26846692
45.

Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Medina-Rosas J, Yap KS, Anderson M, Su J, Touma Z.

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1310-9. doi: 10.1002/acr.22828. Epub 2016 Jul 29. Review.

46.

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus.

Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2015 Oct 24;17:296. doi: 10.1186/s13075-015-0808-x.

47.

SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement.

Touma Z, Gladman DD, Su J, Ibañez D, Urowitz MB.

J Rheumatol. 2015 Aug;42(8):1401-5. doi: 10.3899/jrheum.141088. Epub 2015 Jun 15.

PMID:
26077403
48.

DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC.

Kaka H, Ayearst R, Tran M, Touma Z, Bagovich M, Vinik O, Somaily M, Haddad A, Gladman DD, Chandran V.

Int J Technol Assess Health Care. 2015 Jan;31(1-2):99-102. doi: 10.1017/S0266462315000069. Epub 2015 May 20.

PMID:
25991410
49.

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.

Al Rayes H, Touma Z.

Drug Des Devel Ther. 2014 Nov 17;8:2303-10. doi: 10.2147/DDDT.S49778. eCollection 2014. Review.

50.

Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment.

Touma Z, Urowitz MB, Ibañez D, Gladman DD.

J Rheumatol. 2014 Apr;41(4):688-97. doi: 10.3899/jrheum.130005. Epub 2014 Jan 15.

PMID:
24429170

Supplemental Content

Support Center